Turnstone Biologics Corp

Turnstone Biologics Corp(TSBX)股票分析

$0.355

+0.005 (+1.43%)收盤時

Loading chart…
High
0.365
Open
0.350
VWAP
0.36
Vol
283.77K
Mkt Cap
69.15M
Low
0.350
Amount
101.21K
EV/EBITDA, TTM
0.57

Turnstone Biologics Corp. is a biotechnology company. The Company has been focused on the development of a differentiated approach to treating and curing patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. It has discontinued all sponsored clinical studies evaluating TIDAL-01 for all indications, and pursuit of strategic alternatives to enhance and preserve stockholder value, which may include exploration and evaluation of strategic options like a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions.

估值指標

The current forward P/E ratio for Turnstone Biologics Corp (TSBX) is -1.58, compared to its 5-year average forward P/E of -0.83.

Forward P/E

Fair
5Y Average P/E
-0.83
Current P/E
-1.58
高估
0.05
低估
-1.71

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
0.16
Current EV/EBITDA
0.57
高估
0.88
低估
-0.57

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for TSBX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TSBX

$0.39

情境價格

B

Base

Base · 50%TSBX

$0.33

情境價格

B

Bear

Bear · 25%TSBX

$0.26

情境價格

TSBX FAQ — answered by Alphio AI

Turnstone Biologics Corp. is a biotechnology company. The Company has been focused on the development of a differentiated approach to treating and curing patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. It has discontinued all sponsored clinical studies evaluating TIDAL-01 for all indications, and pursuit of strategic alternatives to enhance and preserve stockholder value, which may include exploration and evaluation of strategic options like a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始